By Matthew Perrone

U.S. health regulators pledged again Thursday to try to ban menthol cigarettes, this time under pressure from African American groups to remove the mint flavor popular among Black smokers.

The Food and Drug Administration has attempted several times to get rid of menthol but faced pushback from Big Tobacco, members of Congress and competing political interests in both the Obama and Trump administrations. Any menthol ban will take years to implement and will likely face legal challenges from tobacco companies.

Thursday’s announcement is the result of a lawsuit filed by anti-smoking and medical groups last summer to force the FDA to finally make a decision on menthol, alleging that regulators had “unreasonably delayed” responding to a 2013 petition seeking to ban the flavor.

The deadline for the agency’s response was Thursday. The FDA said it aims to propose regulations banning the flavor in the coming year.

The action would also ban menthol and fruity flavors from low-cost, small cigars, which are increasingly popular with young people, especially Black teens.

“We will save save hundreds of thousands of lives and prevent future generations from becoming addicted smokers,” said Dr. Janet Woodcock, the FDA's acting commissioner.

She cited research estimates that banning menthol would prevent 630,000 tobacco-related deaths over 40 years, more than a third of them among African Americans.

Menthol is the only cigarette flavor that was not banned under the 2009 law that gave the FDA authority over tobacco products, an exemption negotiated by industry lobbyists. The act did, though, instruct the agency to continue to weigh banning menthol.

The flavor’s persistence has infuriated anti-smoking advocates, who point to research that menthol’s numbing effect masks the harshness of smoking, likely making it easier to start and harder to quit.

The mint-flavored cigarettes are overwhelmingly used by young people and minorities, particularly Black smokers, 85% of whom smoke menthols. That compares to about a third of white smokers.

“The science is there, the data is there, so why are these products still on the market?” said Carol McGruder of the African American Tobacco Control Leadership Council.

Her group sued along with Action on Smoking and Health, the American Medical Association and the National Medical Association, which represents Black physicians.

For decades, companies focused menthol marketing and promotions on Black communities, including sponsoring music festivals and neighborhood events. Company documents released via 1990s litigation also show companies viewed menthol cigarettes as good “starter” products because they were more palatable for teenagers .

“There was a specific, intentional focus on creating the next generation of smokers by making menthol cigarettes available in those communities,” said Dr. Nia Heard-Garris, who chairs the American Academy of Pediatrics’ group on minority health and equity.

Share:
More In Business
Morning Consult Releases U.S. Economic Outlook for November
Almost 2 years into the pandemic, supply chain woes continue to wreak havoc on our everyday lives. From groceries to chip shortages, both consumers and retailers are feeling the strain with prices only climbing as a result. Data intelligence company Morning Consult is out with its U.S. Economic Outlook for November revealing just how much of a threat these hold-ups could pose to the greater economic recovery. John Leer, Chief Economist at Morning Consult joined Cheddar's Opening Bell.
Economic Impact of Biden's $1.2 trillion Infrastructure Bill
After many years and at least two presidents hoping to overhaul America's infrastructure, congress finally came to an agreement. The House passed the bipartisan infrastructure bill late Friday, receiving thirteen republican votes but failing to earn votes from the six progressive squad members. Joseph Zeballos-Roig, Economics Reporter at Insider joined Cheddar's Opening Bell to discuss the economic impact of the bill.
Regeneron Joins Battle Against COVID-19, Releases Stats on New COVID Treatment
The world hit a grim milestone on Monday, with COVID-19 cases surpassing a quarter of a billion worldwide. As cases increase, the fight to beat the virus continues as well, with a number of medical breakthroughs coming out over the last few months in the form of pills from Pfizer and Merck. Regeneron is now the latest company to join the fight, recently releasing new data on a covid antibody cocktail. Professor Peter Pitts, former FDA Associate Commissioner and the founder of the Center for Medicine in the Public Interest breaks down the differences between the 3 treatments and why vaccines are still among the fire line of defense.
Peloton Stock Continues Steep Drop as It Loses More Than $10B in Value
Doug Astrop, managing partner at Exponential Investment Partners, joined Cheddar to discuss Peloton's precipitous price drop, and whether the company can recover as the at-home workout trend tapers off. "They've lowered the prices on their equipment to try to attract a bigger audience because ultimately they're sort of headed to this Apple ecosystem model where they can monetize a loyal customer base," he said. Astrop noted that he believes there is a reality where the in-person gym experience and Peloton's at-home programs can co-exist.
Markets Look to Continue Record Run
Bill Stone, Chief Investment Officer at Glenview Trust Company, joined Wake Up With Cheddar to break down markets headlines ahead of the start of the trading week.
Load More